NX PharmaGen Invested 2012

NX PharmaGen has developed a novel molecular diagnostics platform for preterm birth, cancer and other diseases.

The NeXosome™ Platform enables the collection of valuable diagnostic data via the analysis of biomarker-containing microvesicles (a.k.a. exosomes) shed from placental, tumor, or diseased cells into the bloodstream. The blood-based NeXosome™ Preterm Birth Assay has been shown to identify pregnancies at-risk for preterm delivery as early as 15-17 weeks gestation in both pilot university studies and confirmatory, independent, blinded third party studies. The NeXosome Platform can be leveraged to produce a series of products that will enable the time series evaluation of the molecular machinery of a tumor through the phases of screening, diagnosis, drug selection, treatment response, and tumor recurrence. Visit www.nxpharmagen.com.


http://www.nxpharmagen.com


Looking for Funding?

VisionTech Partners may be able to help. Through VisionTech Angels and a broad network of investors and business resources, our goal is to help promising ventures succeed. We focus on early stage and early growth technology-based companies in Indiana and the Midwest.

If you have questions or would like more information, Contact Us. If you’re ready to start the process, Submit Your Business Plan using the secure website of Gust, the global platform for angel investing. We look forward to hearing from you!